Pharvaris NV
NASDAQ:PHVS
Pharvaris NV
Stock-Based Compensation
Pharvaris NV
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharvaris NV
NASDAQ:PHVS
|
Stock-Based Compensation
€16.2m
|
CAGR 3-Years
26%
|
CAGR 5-Years
167%
|
CAGR 10-Years
N/A
|
|
Pharvaris NV
Glance View
Pharvaris NV is a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 34 full-time employees. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
See Also
What is Pharvaris NV's Stock-Based Compensation?
Stock-Based Compensation
16.2m
EUR
Based on the financial report for Dec 31, 2024, Pharvaris NV's Stock-Based Compensation amounts to 16.2m EUR.
What is Pharvaris NV's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
167%
Over the last year, the Stock-Based Compensation growth was 52%. The average annual Stock-Based Compensation growth rates for Pharvaris NV have been 26% over the past three years , 167% over the past five years .
